Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of December 2022, with the filing date recorded as December 15, 2022.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this specific report does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed in this filing is the submission of four Change of Director's Interest Notices (Exhibit 99.1). No other operational or financial changes are detailed in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves primarily to incorporate the Director's Interest notices into the company's existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the four Director's Interest changes referenced in Exhibit 99.1.
- Confirm the status of the company's active Registration Statements (Form S-8 and Form F-3) into which this report is incorporated.
- Review the most recent Form 20-F for comprehensive financial data, as this Form 6-K does not include financial statements.